The study of the therapeutic benefits of plasma transfusion of a cured person from infectious diseases began in the 20th century.2 As new antibiotics, antiviral agents, and vaccines are developed, administration of convalescent plasma is not a common treatment, but it can be still an important treatment in the absence of specific treatment of new infectious diseases.3 Over the decades, convalescent plasma has proved its effectiveness as a potential treatment in patients with MERS-CoV,4 H1N15 and H5N1 avian flu,5 and SARS-CoV.6 A systemic review and meta-analysis to evaluate the clinical effects of convalescent plasma shows a statistically significant reduction of mortality.1 In this context, convalescent plasma can be a promising treatment option for severe COVID-19 patients.